Title	Nucleic Acid Therapeutics in Cancer [electronic resource] / edited by Alan M. Gewirtz
Imprint	Totowa, NJ : Humana Press : Imprint: Humana Press, 2004
Connect to	http://dx.doi.org/10.1007/978-1-59259-777-2
Descript	X, 221 p. online resource

The development of effectively targeted and efficiently delivered nucleic acids promises important advances in the diagnosis and treatment of human malignancies. In Nucleic Acid Therapeutics in Cancer, leading researchers, academic physicians, and clinicians clearly and succinctly review the important issues underlying the therapeutic use of nucleic acid-mediated gene silencing. Topics range from basic methodology and delivery to targeting methods and specific clinical targets. The authors thoroughly explain the latest developments in RNA biology, as well as the underpinnings of RNA interference, oligodeoxynucleotide delivery into cells, and strategies for targeting these molecules to accessible regions within the mRNA. They also provide some examples of how these new therapeutic compounds are being used clinically. Concise yet highly readable, Nucleic Acid Therapeutics in Cancer offers those who require a cutting-edge critical synthesis not only a state-of-the-art account of this promising field, but also an illuminating introduction to their emerging therapeutic uses

I. Introduction and Perspective -- 1 Antisense Methodology: An Assessment After 25 Years -- 2 Nucleic Acid Therapeutics: An Introduction -- II. Basic Methodology -- 3 Targeted Genome Modification Via Triple Helix Formation -- 4 Therapeutic Applications of Ribozymes -- 5 Use of Catalytic DNA in Target Validation and Therapeutics -- 6 Targeted Destruction of Small, Stable RNAs: Principles Applicable to Antisense Therapies -- 7 Mechanism of Action of Antisense RNA in Eukaryotic Cells -- III. Delivery -- 8 The Transport of Oligonucleotides Into Cells -- 9 Peptide-Mediated Delivery of Antisense Oligonucleotides and Related Material -- 10 Molecular Vectors for Gene Delivery to Cancer Cells -- IV. Targeting -- 11 Considerations on the Design of Antisense Oligonucleotides -- 12 Identification of Hybridization Accessible Sequence in Messenger RNA -- V. Clinical Targets -- 13 Nucleic Acids As Gene Targeting Therapeutics -- 14 LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen): Phosphorothioate Antisense Oligonucleotides With Pleiotropic Mechanisms of Action -- 15 Antisense Protein Kinase A-RI? Restores Normal Signal Transduction Signatures to Inhibit Tumor Growth